NEW YORK, April 3 - Epigenomics has closed a Series C round of financing worth €21 million, or around $ 22.5 million, the company said today.
This third round brings to €56 million the total capital raised by the DNA methylation firm since it was created in 1998. Epigenomics said it will use the funds to further develop its diagnostic products in cancer, as well as its pharmacodiagnostic and research products.
New investor the Wellcome Trust Limited and all existing VC investors--3i Group, Abingworth, Deutsche Venture Capital DVC, MPM Capital, and tbg--participated in the round.